Uncategorized

Axiom plans Hong Kong IPO, hoping to carve new path for US biotechs

Published

2 weeks ago

on

July 21, 2026

By

Temp User

Axiom Biosciences is thinking outside of the box, betting on a public debut in Hong Kong to raise capital and grow into a global company.

Related Topics:

Leave a Reply

Fierce Biotech4 months ago

Scientists turn pig semen extract into eye drops that kill cancer in mice
Uncategorized9 years ago

These ’90s fashion trends are making a comeback in 2017
Endpoints News4 months ago

Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
Uncategorized4 months ago

Novartis buys Synnovation’s PI3Kα inhibitors for $3 billion
Uncategorized9 years ago

According to Dior Couture, this taboo fashion accessory is back
Uncategorized9 years ago

Phillies’ Aaron Altherr makes mind-boggling barehanded play

Exit mobile version